-
US envoy on West Bank visit says Israel has responsibility for Palestinians
-
Commemoration held for late Serbian war criminal Ratko Mladic
-
Ethiopian Miss World contestant spotlights pain of sister's murder
-
Russell on top ahead of Hamilton in final Italian GP practice
-
'Leader' Raphinha rising to Barca striker challenge
-
Motorsport governing body rejects Alpine boss's claims of impartiality
-
Oasis fans gather in Venice for band reunion film
-
Flick hoping Barca's Yamal can face Valencia after knock
-
Two Nepal rescues revive hopes 10 days after flood
-
Trump envoys land in Moscow for Russia-Ukraine peace push
-
Pogacar to miss worlds after season-ending Vuelta crash
-
Russia hits Kyiv airports as Trump peace envoys awaited
-
Greenwood, Guendouzi handed bans after Fenerbahce-Lyon brawl
-
Nepal tunnel rescue revives hopes 10 days after flood
-
In Iceland, the mystery of the poet, the tomb and the Danish grocer
-
Indonesia rescues second orangutan mother and baby from wildfire
-
Ratko Mladic: Bosnian Serb commander to convicted war criminal
-
Box office magnet Robert Pattinson appears in paedophile thriller
-
Bolivian army base blasts kill two, wound dozens
-
How haze from Indonesian fires impacts Southeast Asia
-
Alcaraz, Sabalenka into US Open last 16 as Williams sisters lose on return
-
Trump sends envoys to Moscow, Kyiv with new plan to 'end war'
-
Williams sisters fall in thrilling return to US Open doubles
-
'Mini-dictatorship': Students slam Argentina-run residence in Paris
-
Bangladesh measles toll nears grim 1,000-child mark
-
The disgraced banker stirring the pot in Brazil's Supreme Court
-
Bolivia farmers return to streets over diesel price hikes
-
Panama Canal begins reducing crossings due to El Nino
-
Tetris distances itself from controversial White House 'arcade' games
-
Trump again seeks to remove protections for wolves
-
Africa bigger, US smaller - UN adopts new map
-
'Getting there' - Alcaraz into US Open last 16 along with Sabalenka
-
Bad weather will not affect All Blacks, says captain Savea
-
Isak ready to show world his quality, says Van Dijk
-
Mbappe misses penalty as Parrott lifts Betis past Real Madrid
-
Stuttgart cruise past Cologne to bounce back from Bayern thumping
-
PSG still winless in Ligue 1 as Monaco go top
-
'Smart, aggressive' Alcaraz into US Open last 16
-
Defending champion Alcaraz reaches last 16 at US Open
-
Isak fires Liverpool to first win under Iraola at Ipswich
-
Lyles ends season before Budapest due to injury flare ups
-
Stocks slip as robust US jobs data stokes rate hike odds
-
US Republicans announce probe into environment groups
-
Mistrial declared in case of US woman who killed her three children
-
Sabalenka survives despite 'tricky' weed smell at US Open
-
Seville, Alfred win at Diamond League finals, Duplantis hit with injury
-
S&P Revises Outlook on Freedom Holding Corp. and Core Subsidiaries to Positive
-
Moody’s Assigns First-Time Insurance Financial Strength Ratings to Freedom Insurance and Freedom Life
-
Job growth but record-high diesel prices -- Trump's midterms mixed bag
-
Trump says envoys taking plan to 'end the war' to Moscow, Kyiv
Pharma-Bio Serv Announces Full Year Results
DORADO, PUERTO RICO / ACCESS Newswire / January 29, 2025 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a regulatory affairs, quality, compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, medical device, cosmetic, food and allied products industries, today announced that revenues for the year ended October 31, 2024 were approximately $9.5 million, a decrease of approximately $7.5 million when compared to last year. Additionally, a net loss for the year ended October 31, 2024 was reported of approximately $0.8 million, compared to a net income of approximately $1.3 million for last year.
"While 2024 was a challenging year for the industries we serve, particularly in terms of new investments and projects, we took deliberate steps to address these concerns. We concentrated our efforts on higher-value services and redirected resources toward business development, including the adoption of advanced technologies. These initiatives are designed to strengthen our connections with new and existing clients and explore prospective markets in innovative ways. As we move forward, we believe these measures position us well for potential growth in 2025," stated Mr. Sanchez, Chief Executive Officer of the Company.
Mr. Sanchez continued, "Moreover, we remain financially strong and optimistic about the future of our industry. Accordingly, as announced earlier today, the Company's Board of Directors approved a Special Dividend of $0.075 per share payable on or about March 20, 2025. We believe this dividend underscores our commitment to deliver value to our shareholders and our confidence in our business plan."
About Pharma-Bio Serv, Inc.
Pharma-Bio Serv services the Puerto Rico, United States, Europe and Latin America markets. Pharma-Bio Serv's core business is FDA and international agencies regulatory compliance consulting related services. The Company's global team includes leading engineering and life science professionals, quality assurance managers and directors.
Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the U.S. federal securities laws, which statements may include information regarding the plans, intentions, expectations, future financial performance, or future operating performance of Pharma-Bio Serv. Forward-looking statements are based on the expectations, estimates, or projections of management as of the date of this earnings announcement. Although Pharma-Bio Serv's management believes these expectations, estimates, or projections to be reasonable as of the date of this earnings announcement, forward-looking statements are inherently subject to significant business risks, economic uncertainties, competitive uncertainties, and other factors, which could cause its actual results or performance to differ materially from what may be expressed or implied in the forward-looking statements. Important factors that could cause Pharma-Bio Serv's actual results or performance to differ materially from the forward-looking statements include those set forth in the "Risk Factors" section of Pharma-Bio Serv's most recent Annual Report on Form 10-K, and in its other filings with the Securities and Exchange Commission, which filings are available on www.sec.gov. Pharma-Bio Serv disclaims any intention or obligation to update or revise any forward-looking statements to reflect subsequent events and circumstances, except to the extent required by applicable law.
Company Contact:
Pedro J. Lasanta
Chief Financial Officer
787 278 2709
SOURCE: Pharma-Bio Serv, Inc.
View the original press release on ACCESS Newswire
T.Perez--AT